A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes

Launched by FIRST INSTITUTE OF ALL MEDICINES · Aug 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying whether a treatment called biophoton therapy can help people with type 2 diabetes. Biophoton therapy uses special devices called Tesla BioHealing® Biophoton Generators, which are designed to deliver light-based treatment. The study will include about 46 volunteers who have been diagnosed with type 2 diabetes and are between 18 and 70 years old. To join, participants need to be willing to follow the study’s steps, speak English, and not have serious other health issues or be involved in other medical trials.

If you take part, you’ll be randomly placed into one of two groups without knowing which one you’re in: one group will start with the real biophoton therapy device, and the other will use a similar device that doesn’t deliver the treatment (a placebo). After four weeks, both groups will use the real device for another four weeks. The study lasts about two months in total. Throughout the study, the doctors and staff won’t know who is using the real or placebo device during the first two weeks to keep the results fair. Before joining, you’ll review and sign a consent form and talk with the study team to make sure you understand what’s involved. This study is still recruiting volunteers who meet these requirements.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willing and able to give informed consent for participation in the trial.
• • Is able and willing to comply with all trial requirements.
• • Male or female aged 18-70 years old without major diseases.
• • An adult clinically diagnosed with DM2
• • Participants must not be heavy users of Tesla BioHealing devices; enrollment will be determined by the clinical team based on an evaluation of the participant's prior device usage.
• • Must be fluent in English.
• Exclusion Criteria:
• • Untreated psychiatric disturbances that would affect trial participation as judged by research medical professionals.
• • Is participating in another investigational drug or device trial